[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"FzioMed\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100561731",false,"NCT06593977","Evaluation of Dynavisc in Pain Reduction Following Revision Surgery for Persistent or Recurrent Carpal Tunnel Syndrome","A Multicenter, Evaluator-Blinded, Randomized Evaluation of DYNAVISC in Pain Reduction Following Revision Surgery for Persistent or Recurrent Carpal Tunnel Syndrome","Inclusion criteria\n\n* Signed and dated informed consent form;\n* Stated willingness to comply with all study procedures and availability for the duration of the study;\n* Aged 18-65 years of age;\n* In good general health;\n* Patients experiencing recurrence or persistence of pain in the ipsilateral hand after previous carpal tunnel release for surgical treatment of primary carpal tunnel syndrome;\n* All of the following physical examination tests must be performed; at least one must be positive:\n\n  1. Physical examination demonstrates positive Phalen test;\n  2. Physical examination demonstrates positive Tinel's test;\n  3. Physical examination demonstrates positive monofilament test;\n* ENMG demonstrates median nerve velocity and deviation consistent with the diagnosis of carpal tunnel syndrome.\n\nExclusion criteria\n\n* Inability to understand the clinical trial and\u002For sign the Informed Consent;\n* Unable or unwilling to attend all of the study prescribed visits and data collection forms;\n* Active infection requiring medication;\n* Drug requiring diabetes mellitus;\n* Collagenopathies;\n* Hypothyroidism requiring medication;\n* Rheumatoid arthritis requiring medication;\n* Autoimmune disease requiring medication;\n* Cervical nerve compression;\n* Hematopoietic disorders;\n* Lacertus fibrosis;\n* Psychiatric disorder requiring medical treatment;\n* Subject of workers compensation claim;\n* History of cancer, except for basal or squamous cell skin cancer;\n* Known allergic reactions to components of DYNAVISC;\n* Actively participating in another clinical trial.","ALL","18 Years","65 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","The trial will evaluate the efficacy of DYNAVISC in subjects with a diagnosis of persistent or recurrent carpal tunnel syndrome. This is a prospective, multicenter, randomized, evaluator-blinded clinical trial. Results will be stratified based on the method used for median nerve coverage: Group 1 (standard of care surgery followed by DYNAVISC surrounding the median nerve, n=25 participants), Group 2 (standard of care surgery followed by coverage of the median nerve with a hypothenar fat pad flap, n=25",[26],"Carpal Tunnel Syndrome (CTS)",[28,29],"carpal tunnel","revision","RECRUITING","2026-03-31",{"date":33,"type":34},"2026-04-06","ACTUAL",{"date":36,"type":20},"2026-03-26",{"date":38,"type":20},"2027-10",{"name":40,"class":41},"FzioMed","INDUSTRY",4,""]